Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

Similar articles for PubMed (Select 23501099)

1.

[Multidisciplinary clinical management for prophylactic mastectomy: views of women from one centre in Quebec City].

Dorval M, Pelletier S, Bouchard K, Desbiens C, Chiquette J.

Bull Cancer. 2013 Mar;100(3):201-11. doi: 10.1684/bdc.2013.1708. French.

PMID:
23501099
2.

Decision-making process of women carrying a BRCA1 or BRCA2 mutation who have chosen prophylactic mastectomy.

McQuirter M, Castiglia LL, Loiselle CG, Wong N.

Oncol Nurs Forum. 2010 May;37(3):313-20. doi: 10.1188/10.ONF.313-320.

PMID:
20439215
3.

One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery).

Lodder LN, Frets PG, Trijsburg RW, Meijers-Heijboer EJ, Klijn JG, Seynaeve C, van Geel AN, Tilanus MM, Bartels CC, Verhoog LC, Brekelmans CT, Burger CW, Niermeijer MF.

Breast Cancer Res Treat. 2002 May;73(2):97-112.

PMID:
12088120
4.

Satisfaction with prophylactic mastectomy and breast reconstruction in genetically predisposed women.

Bresser PJ, Seynaeve C, Van Gool AR, Brekelmans CT, Meijers-Heijboer H, van Geel AN, Menke-Pluijmers MB, Duivenvoorden HJ, Klijn JG, Tibben A.

Plast Reconstr Surg. 2006 May;117(6):1675-82; discussion 1683-4.

PMID:
16651934
5.

Support needs and acceptability of psychological and peer consultation: attitudes of 108 women who had undergone or were considering prophylactic mastectomy.

Patenaude AF, Orozco S, Li X, Kaelin CM, Gadd M, Matory Y, Mayzel K, Roche CA, Smith BL, Farkas W, Garber JE.

Psychooncology. 2008 Aug;17(8):831-43. doi: 10.1002/pon.1279.

6.

Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.

Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van 't Veer L, Garber JE, Evans GR, Narod SA, Isaacs C, Matloff E, Daly MB, Olopade OI, Weber BL.

J Clin Oncol. 2004 Mar 15;22(6):1055-62. Epub 2004 Feb 23.

7.

Clinical experience of prophylactic mastectomy followed by immediate breast reconstruction in women at hereditary risk of breast cancer (HB(O)C) or a proven BRCA1 and BRCA2 germ-line mutation.

Contant CM, Menke-Pluijmers MB, Seynaeve C, Meijers-Heijboer EJ, Klijn JG, Verhoog LC, Tjong Joe Wai R, Eggermont AM, van Geel AN.

Eur J Surg Oncol. 2002 Sep;28(6):627-32.

PMID:
12359199
8.

Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.

Meijers-Heijboer H, Brekelmans CT, Menke-Pluymers M, Seynaeve C, Baalbergen A, Burger C, Crepin E, van den Ouweland AW, van Geel B, Klijn JG.

J Clin Oncol. 2003 May 1;21(9):1675-81.

PMID:
12721241
9.

Breast cancer risk perception among women who have undergone prophylactic bilateral mastectomy.

Metcalfe KA, Narod SA.

J Natl Cancer Inst. 2002 Oct 16;94(20):1564-9.

10.

Prophylactic mastectomy for the prevention of breast cancer.

Lostumbo L, Carbine N, Wallace J, Ezzo J.

Cochrane Database Syst Rev. 2004 Oct 18;(4):CD002748. Review. Update in: Cochrane Database Syst Rev. 2010;(11):CD002748.

PMID:
15495033
11.

Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.

Metcalfe KA, Lubinski J, Ghadirian P, Lynch H, Kim-Sing C, Friedman E, Foulkes WD, Domchek S, Ainsworth P, Isaacs C, Tung N, Gronwald J, Cummings S, Wagner T, Manoukian S, Møller P, Weitzel J, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.

J Clin Oncol. 2008 Mar 1;26(7):1093-7. doi: 10.1200/JCO.2007.12.6078. Epub 2008 Jan 14.

12.

Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers.

Hartmann LC, Sellers TA, Schaid DJ, Frank TS, Soderberg CL, Sitta DL, Frost MH, Grant CS, Donohue JH, Woods JE, McDonnell SK, Vockley CW, Deffenbaugh A, Couch FJ, Jenkins RB.

J Natl Cancer Inst. 2001 Nov 7;93(21):1633-7.

13.

Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1/2 gene testing.

Tercyak KP, Peshkin BN, Brogan BM, DeMarco T, Pennanen MF, Willey SC, Magnant CM, Rogers S, Isaacs C, Schwartz MD.

J Clin Oncol. 2007 Jan 20;25(3):285-91. Epub 2006 Dec 11.

14.

Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients.

Grann VR, Panageas KS, Whang W, Antman KH, Neugut AI.

J Clin Oncol. 1998 Mar;16(3):979-85.

PMID:
9508180
15.

International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.

Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, Gronwald J, Lynch H, Moller P, Ghadirian P, Foulkes WD, Klijn J, Friedman E, Kim-Sing C, Ainsworth P, Rosen B, Domchek S, Wagner T, Tung N, Manoukian S, Couch F, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.

Int J Cancer. 2008 May 1;122(9):2017-22. doi: 10.1002/ijc.23340.

16.

Risk-reducing strategies for women carrying BRCA1/2 mutations with a focus on prophylactic surgery.

Salhab M, Bismohun S, Mokbel K.

BMC Womens Health. 2010 Oct 20;10:28. doi: 10.1186/1472-6874-10-28. Review.

17.

[The effect of prophylactic mastectomy with recontruction on quality of life in BRCA positive women].

Spurná Z, Dražan L, Foretová L, Dvorská L.

Klin Onkol. 2012;25 Suppl:S74-7. Czech.

PMID:
22920211
18.

Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.

Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, Bartels CC, Verhoog LC, van den Ouweland AM, Niermeijer MF, Brekelmans CT, Klijn JG.

N Engl J Med. 2001 Jul 19;345(3):159-64.

19.

Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.

Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K, Lu K, Meric-Bernstam F, Amos C, Strong L, Arun B.

Cancer. 2006 Dec 15;107(12):2745-51.

20.

Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers.

Friebel TM, Domchek SM, Neuhausen SL, Wagner T, Evans DG, Isaacs C, Garber JE, Daly MB, Eeles R, Matloff E, Tomlinson G, Lynch HT, Tung N, Blum JL, Weitzel J, Rubinstein WS, Ganz PA, Couch F, Rebbeck TR.

Clin Breast Cancer. 2007 Dec;7(11):875-82. doi: 10.3816/CBC.2007.n.053.

PMID:
18269778
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk